2 results
Approved WMOCompleted
Dual Primary Objectives:* To determine if apixaban is noninferior to VKA (INR target range 2.0-3.0) on the combined endpoint of ISTHmajor or clinically relevant non-major bleeding in patients with NVAF who develop ACS or undergo PCI withplanned…
Approved WMOPending
The primary objective is to determine the efficacy of the neuroprotectant, nerinetide in:• Reducing global disability in participants with acute ischemic stroke (AIS)